-
The Startup That Wants To Bring Expert Networks To Every Investor
Wednesday, October 19, 2016 - 4:40pm | 1522Read More...Professional investors spend over $600 million per year speaking with the most qualified experts before risking their capital. Until now, this information was unavailable to most investors. But Slingshot Insights is trying to change that by offering every investor access to the same insiders...
-
Trading Alert: Collegium Pharmaceuticals May See Increased Activity Thursday
Wednesday, August 17, 2016 - 3:49pm | 373Read More...Biotech traders may want to keep an eye on Collegium Pharmaceuticals Inc (NASDAQ: COLL) on Thursday morning, as the stock may see increased activity due to an expert networking call between investors and an expert discussing the company's drug Xtampza ER. On April 27, the FDA approved Collegium's...
-
How To Get A 1-On-1 With An Expert On SAGE-547
Thursday, July 28, 2016 - 5:24pm | 244Read More...Slingshot Insights, a web community that connects investors with professional primary research tools and cost-shared expert interviews, will be conducting an expert call to talk about the trial success of SAGE Therapeutics Inc (NASDAQ: SAGE)’s SAGE-547 on Friday. The call will take a look...
-
Slingshot Insights Expert Discusses Sustol Delays
Thursday, July 21, 2016 - 5:30pm | 266Read More...Heron Therapeutics Inc (NASDAQ: HRTX)'s Sustol has endured a seemingly endless delay in its FDA approval process, and Slingshot Insights conducted an expert conference call on Thursday to discuss the matter. In addition to the potential for FDA approval, the expert discussed where Sustol...
-
What's The Market Potential For Relypsa Now That AstraZeneca's ZS-9 Is Indefinitely On Hold?
Friday, July 8, 2016 - 2:33pm | 297Read More...In late May, shares of Relypsa Inc (NASDAQ: RLYP) soared when the FDA rejected AstraZeneca plc (ADR) (NYSE: AZN)’s hyperkalemia drug ZS-9. The market is betting that the rejection will be good news for Relypsa’s Veltassa, which also treats hyperkalemia. Slingshot Insights recently held...
-
Slingshot Insights' Expert Conference Call On Lipocine
Friday, June 17, 2016 - 3:03pm | 301Read More...Lipocine Inc (NASDAQ: LPCN)’s LPCN-1021’s PDUFA date is coming up on June 28. Given the major potential near-term catalyst, Slingshot Insights recently conducted an expert conference call with a professor, researcher and a clinical director from the Department of Medicine at Johns...
-
Here's Why You Should Watch For Movement In Lipocine Tomorrow
Wednesday, June 8, 2016 - 4:31pm | 309Read More...Traders interested in biotech news should watch out for headlines tomorrow out of Lipocine Inc (NASDAQ: LPCN). Lipocine has been developing a new treatment for hypogonadism, a disease causing a lack of endogenous testosterone. In anticipation of the drug LPCN-1021 nearing its PDUFA date,...
-
Dynavax, GlaxoSmithKline Battling In Same Industry: Who Will Win?
Tuesday, February 23, 2016 - 1:30pm | 320Read More...Slingshot Insights recently conducted an interview with Dr. Ashwin Balagopal, assistant professor of medicine at the Johns Hopkins University School of Medicine about the impact that Dynavax Technologies Corporation (NASDAQ: DVAX)’s HBV-23 will have on the HBV vaccine market, particularly...
-
Will Merck Encroach On Gilead's Harvoni Territory?
Tuesday, February 23, 2016 - 12:36pm | 363Read More...Slingshot Insights recently conducted an interview with Dr. Bruce Bacon, Professor of Internal Medicine at Saint Louis University School of Medicine about the impact that Merck & Co., Inc. (NYSE: MRK)’s Zepatier will have on the HCV market, particularly when it comes to Gilead Sciences...
